

A Two-Stage Kernel Machine Regression Model for Integrative Analysis of Alpha Diversity

Runzhe Li



Department of Biostatistics
Johns Hopkins Bloomberg School of Public Health

March 23, 2020

1 Introduction

- Human microbiota and microbiome
- Integrative analysis
- Alpha diversity

2 Methods

- Kernel regression models
- Association testing

3 Results

- Simulation studies
- Simulation results

4 Summary

1 Introduction

- Human microbiota and microbiome
- Integrative analysis
- Alpha diversity

2 Methods

- Kernel regression models
- Association testing

3 Results

- Simulation studies
- Simulation results

4 Summary

Introduction: Human microbiota and microbiome

- Human microbiota: ecological communities of microorganisms that reside in and on human body.
- Human microbiome: the collective genomes of resident microorganisms.




Figure: human skin microbiota ¹

¹ <https://en.wikipedia.org/wiki/Microbiota>

Introduction: Integrative Analysis

- The study to examine α -diversity measures between HIV⁻ and HIV⁺ individuals. 22 studies were identified with 17 datasets available for analysis, yielding 1032 samples. ²




Figure: Figures from a study to investigate associations between gut microbial α -diversity and HIV status

² Tuddenham, S. A., Koay, W. L. A., Zhao, N., White, J. R., Ghanem, K. G., and Sears, C. L. (2020). The Impact of Human Immunodeficiency Virus Infection on Gut Microbiota α -Diversity: An Individual-level Meta-analysis. *Clinical Infectious Diseases*

Introduction: Integrative Analysis

- Analyzing data from **individual** study
 - small sample size
 - does not account for study heterogeneity
 - inconsistent results due to the technical variability.
- Developing Integrative analysis from **multiple** studies
 - address the potential biases
 - boost statistical power and recover signals




Figure: Integrative analysis leveraging information from multiple studies

Introduction: Alpha diversity

- Alpha diversity: summarizes the diversity **within** an ecological community
 - Species Richness: *how many?*
 - Species Evenness: *how different?*

Simple example:



Figure: A toy example of species richness and evenness ³

³ <http://users.unimi.it/dmora/materiali/ANU2012/BioInfoTools.pdf>

Introduction: Questions of interest

- Our goal: identify the association between phenotype of interest and alpha diversity via integrative analysis of multiple studies.
- different hypothesis testings:
 - common effect test
 - heterogeneity test
 - joint test

1 Introduction

- Human microbiota and microbiome
- Integrative analysis
- Alpha diversity

2 Methods

- Kernel regression models
- Association testing

3 Results

- Simulation studies
- Simulation results

4 Summary

Stage One

The association between alpha-diversity and HIV status via a linear mixed model

$$y_{ij} = x_{ij}\beta_i + z_{ij}^\top \gamma + h_i + \epsilon_{ij}$$

$$Y_{N \times 1} = X_{N \times p}\beta_{p \times 1} + Z_{N \times q}\gamma_{q \times 1} + h_{N \times 1} + \epsilon_{N \times 1}$$

where $\beta(p \times 1)$, $\gamma(q \times 1)$ are regression coefficients for fixed effects. $h_i \sim N(0, \sigma_h^2)$ are study-specific random effect which captures the difference between studies, $\epsilon_{ij} \sim N(0, \sigma_e^2)$ are error terms.

Stage Two

We allow β_i to vary according to the study-specific characteristics

$$\beta_i = \beta_0 + f(G_i)$$

where $f(\cdot)$ is a function in reproducing kernel Hilbert space generated by a positive semidefinite kernel function $K(\cdot, \cdot)$. For example, a linear kernel $K(G_i, G_{i'}) = \sum_{j=1}^r G_{ij} G_{i'j}$ could measure the similarity between study i and study i' .

Methods: Association testing

Consider a special case where the second stage is:

$$\beta = \beta_0 \cdot \mathbf{1}_p + G\alpha, \alpha \sim N(0, \tau^2 I_{r \times r})$$

where $\beta \sim N(\beta_0 \cdot \mathbf{1}_p, \tau^2 K)$ and $K = GG'$.

Methods: Association Testing

Plug in and we can derive:

$$Y = (X1_p\beta_0 + Z\gamma) + (XG\alpha + h) + \epsilon$$
$$\alpha \sim N(0, \tau^2 I)$$

We are interested in the following hypothesis testings.

- ① (test for common effect) test $\beta_0 = 0$ under $\tau^2 = 0$
- ② (test for heterogeneity) test $\tau^2 = 0$ under $\beta_0 = 0$
- ③ (test for heterogeneity) test $\tau^2 = 0$ without constraint on β_0
- ④ (joint test) combine test 1 and 3
- ⑤ (test for common effect) test $\beta_0 = 0$ without constraint on τ

1. (Burden test) test $\beta_0 = 0$ under $\tau^2 = 0$

$$Q_{\beta_0} = (Y - Z\hat{\gamma})^\top \hat{\Sigma}_0^{-1} X 1_p 1_p^\top X^\top \hat{\Sigma}_0^{-1} (Y - Z\hat{\gamma})$$

where the null MLE: $\hat{\gamma}$, $\hat{\sigma}_h^2$, $\hat{\sigma}_e^2$, and estimated null covariance matrix: $\hat{\Sigma}_0 = \hat{\sigma}_h^2 H + \hat{\sigma}_e^2 I_N$ could be derived under the null model $Y = Z\gamma + h + \epsilon$.

We can further show that Q_{β_0} follows a scaled chi-square distribution with freedom 1.

2. (SKAT test) test $\tau^2 = 0$ under $\beta_0 = 0$

$$Q_{\tau_0^2} = (y - Z\hat{\gamma})^\top \hat{\Sigma}_0^{-1} X K X^\top \hat{\Sigma}_0^{-1} (Y - Z\hat{\gamma})$$

where $\hat{\gamma}$ and $\hat{\Sigma}_0$ are still derived under the null model $Y = Z\gamma + h + \epsilon$.

According to Davies method ⁴, Q_{τ^2} follows a mixture of chi-square distribution.

⁴Davies, R. B. (1980). The distribution of a linear combination of χ^2 random variables. *Journal of the Royal Statistical Society: Series C (Applied Statistics)*, 29(3), 323-333.

3. (Unconstrained SKAT test) test $\tau^2 = 0$ without constraint on β_0

$$Q_{\tau^2} = (y - \hat{\mu})^\top \hat{\Sigma}^{-1} X K X^\top \hat{\Sigma}^{-1} (y - \hat{\mu})$$

Let $\hat{\mu}$ denote the fitted value, $\hat{\Sigma}$ be the estimated covariance matrix under the model $Y = X1_p\beta_0 + Z\gamma + \epsilon$.

Similarly, we could also show Q_{τ^2} follows a mixture of chi-square distribution.

4. (Optimal Joint Test) test $\beta_0 = 0$ and $\tau^2 = 0$

Let $Q_\rho = \rho Q_{\beta_0} + (1 - \rho)Q_{\tau^2}$, where Q_{β_0} is derived from burden test, and Q_{τ^2} is derived from unconstrained SKAT test. Let p_ρ denote the p-value of Q_ρ . Then the test statistics is

$$T = \min_{0 \leq \rho \leq 1} p_\rho$$

5. (Unconstrained burden test) test $\beta_0 = 0$ without constraint on τ

$$Q_\beta = (Y - Z\hat{\gamma})^\top \hat{\Sigma}_\tau^{-1} X 1_p 1_p^\top X^\top \hat{\Sigma}_\tau^{-1} (Y - Z\hat{\gamma})$$

where $\hat{\Sigma}_\tau = \hat{\sigma}_h^2 H + \hat{\sigma}_e^2 I_N + \hat{\tau}^2 X K X^\top$ could be derived from the model $Y = Z\gamma + XG\alpha + h + \epsilon$.

Q_β follows a scaled chi-square distribution with freedom 1.

1 Introduction

- Human microbiota and microbiome
- Integrative analysis
- Alpha diversity

2 Methods

- Kernel regression models
- Association testing

3 Results

- Simulation studies
- Simulation results

4 Summary

Results: Simulation Studies

$$y_{ij} = x_{ij}\beta_i + z_{ij}^\top \gamma + h_i + \epsilon_{ij}$$
$$\beta_i = \beta_0 + G_i^\top \alpha, \alpha \sim N(0, \tau^2 I)$$

- Design matrix:
 - X_{ij} : HIV status $\{0, 1\}$
 - Z_{ij} : intercept, MSM $\{0, 1\}$, gender $\{0, 1\}$
 - $G_{p \times r}$: categorical $\{0, 1, 2, 3\}$: primer, sequence, DNA extraction, batch effect
- Parameters
 - $h \sim N(0, \sigma_h^2)$, $\epsilon \sim N(0, \sigma_e^2)$
 - change ratio of h and ϵ
- Sample size and dimensions:
 - # of study: p
 - # of microbiome characteristic: r

Results: Simulation Studies

$$y_{ij} = x_{ij}\beta_i + z_{ij}^\top \gamma + h_i + \epsilon_{ij}$$
$$\beta_i = \beta_0 + G_i^\top \alpha, \alpha \sim N(0, \tau^2 I)$$

- Type I error and power analysis
 - Type I error: $\beta_0 = 0$ and $\tau = 0$
 - Power case I: $\beta_0 \neq 0$ and $\tau = 0$
 - Power case II: $\beta_0 = 0$ and $\tau \neq 0$
 - Power case III: $\beta_0 \neq 0$ and $\tau \neq 0$

Results: Simulation Results

Type I error

	Empirical Type I Error	
level	0.05	0.01
LMM [†]	0.048	0.011
Burden	0.048	0.011
SKAT	0.054	0.006
Unconstrained SKAT	0.045	0.009
Optimal joint test	0.050	0.0095
Unconstrained burden	0.013	0.001

Table: Empirical type I error under 2000 simulations: $r = 3$, $p = 50$, $\sigma_h = 1$, $\sigma_e = 0.5$

[†] the default p-value of linear mixed model only testing for common effect in R.

Results: Simulation Results

Power

Case I : $\beta_0 = 0.1$ and $\tau = 0$




Figure: Power under simulation setting 1

Findings

- sample size increases \rightarrow power increases
- overall performance: LMM, burden $>$ optimal joint test $>$ SKAT
- unconstrained SKAT test has power \approx type I error

Results: Simulation Results

Power

Case II : $\beta_0 = 0$ and $\tau = 0.1$




Figure: Power under simulation setting 2

Findings

- overall performance: optimal joint test, SKAT > unconstrained SKAT > LMM, burden
- unconstrained burden test has power \approx type I error

Results: Simulation Results

Power

Case III : $\beta_0 = 0.1$ and $\tau = 0.1$




Figure: Power under simulation setting 3

Findings

- overall performance: optimal joint test is the most powerful test compared to other burden and variance component test.

1 Introduction

- Human microbiota and microbiome
- Integrative analysis
- Alpha diversity

2 Methods

- Kernel regression models
- Association testing

3 Results

- Simulation studies
- Simulation results

4 Summary

Conclusions


- propose a two-stage kernel machine regression model to associate alpha diversity with the phenotype of interests.
 - Stage one: model the relationship between the alpha diversity and the phenotype via a linear mixed model.
 - Stage two: incorporate the study-specific characteristics through a nonparametric function to allow for the between-study heterogeneity.
- construct several association testing problems.
- design the simulation studies.

Future work

- permutation tests for small sample size adjustment.
- application on real HIV studies.

Acknowledgement

This is joint work with Dr.Ni Zhao.



Ni Zhao

Reference I



Susan A Tuddenham, Wei Li A Koay, Ni Zhao, James R White, Khalil G Ghanem, and Cynthia L Sears.

The impact of human immunodeficiency virus infection on gut microbiota α -diversity: An individual-level meta-analysis.

Clinical Infectious Diseases, 70(4):615–627, 2020.



Amy D Willis.

Rarefaction, alpha diversity, and statistics.

Frontiers in microbiology, 10:2407, 2019.



Hyunwook Koh.

An adaptive microbiome α -diversity-based association analysis method.

Scientific reports, 8(1):1–12, 2018.



Han Chen, Jennifer E Huffman, Jennifer A Brody, Chaolong Wang, Seunggeun Lee, Zilin Li, Stephanie M Gogarten, Tamar Sofer, Lawrence F Bielak, Joshua C Bis, et al.

Efficient variant set mixed model association tests for continuous and binary traits in large-scale whole-genome sequencing studies.

The American Journal of Human Genetics, 104(2):260–274, 2019.



Zhong Wang, Ke Xu, Xinyu Zhang, Xiaowei Wu, and Zuoheng Wang.

Longitudinal snp-set association analysis of quantitative phenotypes.

Genetic epidemiology, 41(1):81–93, 2017.

Reference II



Yu-Ru Su, Chongzhi Di, Stephanie Bien, Licai Huang, Xinyuan Dong, Goncalo Abecasis, Sonja Berndt, Stephane Bezieau, Hermann Brenner, Bette Caan, et al.

A mixed-effects model for powerful association tests in integrative functional genomics.
The American Journal of Human Genetics, 102(5):904–919, 2018.



Ni Zhao, Jun Chen, Ian M Carroll, Tamar Ringel-Kulka, Michael P Epstein, Hua Zhou, Jin J Zhou, Yehuda Ringel, Hongzhe Li, and Michael C Wu.

Testing in microbiome-profiling studies with mirkat, the microbiome regression-based kernel association test.

The American Journal of Human Genetics, 96(5):797–807, 2015.



Michael C Wu, Seunggeun Lee, Tianxi Cai, Yun Li, Michael Boehnke, and Xihong Lin.

Rare-variant association testing for sequencing data with the sequence kernel association test.

The American Journal of Human Genetics, 89(1):82–93, 2011.



Seunggeun Lee, Michael C Wu, and Xihong Lin.

Optimal tests for rare variant effects in sequencing association studies.

Biostatistics, 13(4):762–775, 2012.

A Two-Stage Kernel Machine Regression Model for Integrative Analysis of Alpha Diversity

Runzhe Li



Department of Biostatistics
Johns Hopkins Bloomberg School of Public Health

March 23, 2020